ALLURION TECHNOLOGIES INC
For the period ended Jun 30, 2024. Filed Aug 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 14, 2024
ALUR$0.67-5.6%Stored close · as of Mar 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
The following list of exhibits includes exhibits submitted with this Quarterly Report on Form 10-Q as filed with the SEC and those incorporated by reference to other filings.
| ExhibitNumber | Description | Incorporated by Reference herein from - Form or Schedule | File Number | Exhibit | Filed Date |
|---|---|---|---|---|---|
| 1.1 | Underwriting Agreement, dated as of June 28, 2024, among Allurion Technologies, Inc., Jefferies LLC and TD Securities (USA) LLC, as representatives of the underwriters named therein. | 8-K | 001-41767 | 1.1 | July 1, 2024 |
| 3.1 | Amended and Restated Certificate of Incorporation of Allurion Technologies, Inc. (f/k/a Allurion Technologies Holdings, Inc.) | 8-K | 001-41767 | 3.1 | August 7, 2023 |
| 3.2 | Bylaws of Allurion Technologies, Inc. (f/k/a Allurion Technologies Holdings, Inc.) | 8-K | 001-41767 | 3.2 | August 7, 2023 |
| 3.3 | Certificate of Designations of Preference Rights and Limitations of Series A Non-Voting Convertible Preferred Stock. | 8-K | 001-41767 | 3.1 | July 1, 2024 |
| 4.1 | Warrant Agreement, dated February 4, 2021, between Compute Health Acquisition Corp. and Continental Stock Transfer & Trust Company, as warrant agent. | 8-K | 001-40001 | 4.1 | February 9, 2021 |
| 4.2 | Amendment to Warrant Agreement, dated August 1, 2023, by and between Compute Health and Continental Stock Transfer & Trust Company. | 8-K | 001-41767 | 4.2 | August 7, 2023 |
| 4.3 | Warrant Assignment, Assumption and Amendment Agreement, dated August 1, 2023, by and among Compute Health Acquisition Corp., New Allurion Holdings, Inc., and Continental Stock Transfer & Trust Company. | 8-K | 001-41767 | 4.3 | August 7, 2023 |
| 4.4 | Form of Public Warrant. | 8-K | 001-41767 | 4.1 | July 1, 2024 |
| 4.5 | Form of Private Placement Warrant. | 8-K | 001-41767 | 4.2 | July 1, 2024 |
| 10.1#+ | Note Purchase Agreement dated as of April 14, 2024, by and among Allurion Technologies, Inc., RTW Investments, LP, as agent for the purchasers part thereto from time to time, and Acquiom Agency Services LLC, as collateral agent for the purchasers. | 8-K | 001-41767 | 10.1 | April 17, 2024 |
| 10.2# | Omnibus Amendment, dated as of April 14, 2024, by and among Allurion Technologies, Inc., Allurion Technologies, LLC and certain entities that have engaged RTW Investments, LP as investment manager. | 8-K | 001-41767 | 10.2 | April 17, 2024 |
| 10.3# | First Amendment to Amended and Restated Letter Agreement, dated as of April 14, 2024, by and among Allurion Technologies, Inc., Allurion Technologies, LLC, RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd. and RTW Biotech Opportunities Operating Ltd. | 8-K | 001-41767 | 10.3 | April 17, 2024 |
| 10.4# | First Amendment to Note Purchase Agreement, dated as of April 16, 2024, by and among Allurion Technologies, Inc., RTW Investments, LP, as agent for the purchasers party thereto from time to time, and Acquiom Agency Services LLC, as collateral agent for the purchasers. | 8-K | 001-41767 | 10.4 | April 17, 2024 |
| 10.5 | Subscription Agreement, dated as of June 28, 2024, between Allurion Technologies, Inc. and the investors named therein. | 8-K | 001-41767 | 10.1 | July 1, 2024 |
| 10.6* | Eighth Amendment to 14 Huron Lease, dated as of April 3, 2024, by and between Allurion Technologies, Inc. and Fourteen Huron Drive, LLC. |
| 10.7*†++ | Offer Letter dated May 17, 2024 with Ojas Buch. |
| 31.1* | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 31.2* | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 32.1** | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 32.2** | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
- Filed herewith.
** Furnished herewith
Certain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Registrant agrees to furnish supplementally a copy of all omitted exhibits and schedules to the SEC upon its request.
- Certain provisions or terms of this exhibit (including any exhibits or schedules thereto) have been omitted in accordance with Regulation S-K Item 601(b)(2). The Registrant agrees to furnish supplementally an unredacted copy of any such exhibit or schedule to the SEC upon its request.
++ Portions of this exhibit have been redacted in accordance with Regulation S-K Item 601(a)(6).
† Indicates a management contract or compensatory plan, contract or arrangement.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.